// App-Quantinova.ai

2140 : An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma

Researchers

Presenter

  • Peter M Voorhees

Principal Investigators

  • Robert L. Schlossman

  • Cristina J Gasparetto

  • Jesus G. Berdeja

  • John Morris

  • Douglas A Jacobstein

  • Kenneth C. Anderson

  • Constantine S Mitsiades

  • Jacob P. Laubach

  • Paul G. Richardson

Medical Centers

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Division of Cellular Therapy, Duke University Medical Center, Durham, NC

  • Sarah Cannon Research Institute, Nashville, TN

  • University of Cincinnati Cancer Institute, Cincinnati, OH

  • Unv of North Carolina Lineberger Comp Cancer Ctr, Chapel Hill, NC

  • Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

Companies

  • Prolexys Pharmaceuti

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • PRL-93936

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved